A Two-Part, Open-Label, Fixed-Sequence, Two-Period Crossover Study to Assess the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone After Administration of the Relugolix/Estradiol/Norethindrone Acetate Fixed-Dose Combination Tablet in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix After Administration of a Single 120-mg Dose in Healthy Adult Men
Latest Information Update: 02 Nov 2021
Price :
$35 *
At a glance
- Drugs Erythromycin (Primary) ; Estradiol/norethisterone acetate/relugolix (Primary) ; Relugolix (Primary)
- Indications Endometriosis; Pain; Prostate cancer; Uterine leiomyoma
- Focus Pharmacokinetics
- Sponsors Myovant Sciences
- 30 Aug 2021 Status changed from recruiting to completed.
- 21 Jan 2021 New trial record